Blog - Page 3186 of 5756

WednesdayNov 28, 2012 5:08 pm

The Guitammer Company Inc. (GTMM) Reports Open Market Insider Purchases

The Guitammer Company, a leader in low frequency sound and creator of the award-winning line of ButtKicker® audio transducers, announced today that CEO Mark A. Luden, Chief Financial Officer Rich E. Conn, and Director Walter J. Doyle acquired a collective 156,000 common shares of Guitammer in open market purchases this month. Luden, Conn, and Doyle purchased shares at prices ranging up to $0.35 per share. “Pursuant to Guitammer’s ‘insider trading policy,’ this represented the first opportunity for Walter, Rich and I to complete open market share purchases since the company began trading on the OTCBB,” stated Mark Luden. “Our collective…

WednesdayNov 28, 2012 5:07 pm

Cardium Therapeutics, Inc. (CXM) Moving Rapidly with Excellagen

Excellagen, Cardium’s FDA-cleared highly-refined fibrillar collagen-based topical gel designed to facilitate wound care management for diabetic ulcers and many other types of wounds, has been the center of much of Cardium’s recent activity. The product was selected by Podiatry Today, an award-winning monthly publication on foot care, as one of the top 10 podiatry innovations in 2012, and is considered a very promising tool for accelerating the wound healing process. Cardium recently announced the formation of a Medical Advisory Board for Excellagen, made up of leading practitioners, clinicians, and researchers with diversified expertise in the field of advanced wound care.…

WednesdayNov 28, 2012 5:05 pm

MRI Interventions, Inc. (MRIC) Awarded Frost & Sullivan 2012 Global Company of the Year Award

Commercial stage medical device company MRI Interventions was recognized for its innovative platforms and technologies by receiving the 2012 Global Company of the Year Award in Image-Guided Neural Interventions by Frost & Sullivan, a global business research and consulting firm. The firm Frost & Sullivan presented the award based on established criteria that included degree of innovation with products and technologies, growth strategy excellence, growth implementation excellence, and leadership in customer value. The firm highlighted MRI Interventions’ Clearpoint® system, which provides an integrated platform for performing a range of minimally-invasive neurological procedures under direct, real-time magnetic resonance imaging (MRI) guidance.…

WednesdayNov 28, 2012 5:03 pm

American Apparel, Inc. (APP) Video Chart for Wednesday, November 28, 2012

With a solid day on Tuesday, APP is making a move off a bottom support. The chart is worthy of a look as upward pressure may lead to a test of the first resistance at $1.10. To view the video chart, visit the following link: http://www.qualitystocks.net/videocharts Let us hear your thoughts below:

WednesdayNov 28, 2012 5:01 pm

TNI BioTech, Inc. (TNIB) and Immunotherapy

Just as stem cell technology holds out the current best hope for the regeneration of healthy cells, immunotherapy is becoming the latest best hope for efficiently dealing with diseased cells. Although immunotherapy in its broadest form can be said to date back to the pioneering work of 18th century English physician Edward Jenner, who greatly advanced the ancient but dangerous practice of inoculation, the modern practice of manipulating the body’s own immune system to treat disease is often marked by American surgeon William Coley who developed a rudimentary cancer treatment based on provoking an immune response to bacteria around 1891.…

WednesdayNov 28, 2012 5:00 pm

San Fran’s BART Places Order for 270 AXION International (AXIH) Switch Ties

AXION International Holdings, a green technologies company, today said it has received its third purchase order for an additional 270 ECOTRAX™ switch ties from San Francisco Bay Area Rapid Transit (BART). BART will install the switch ties along its 104 miles of tracks that connect San Francisco with the suburbs. The heavy-rail public transit and subway system is the 5th busiest rapid transit system in the U.S. ECOTRAX ties are made from AXION’s patented 100 percent recycled plastic formulation. Because they are inert, the ties are not subject to rotting or absorption of moisture or insect infestation. “To put this…

WednesdayNov 28, 2012 11:49 am

Vermillion, Inc. (VRML) Appoints Bruce Huebner as Interim CEO

Vermillion, a molecular diagnostics company, announced that director Bruce A. Huebner has been appointed as interim CEO. He is following Gail S. Page, the company’s most recent CEO, who will assist in the transition and serve as a strategic advisor. Mr. Huebner will continue to serve on the board of directors as he assumes his new role. Mr. Huebner has executive management experience in multiple clinical diagnostic companies, including Osmetech Molecular Diagnostics, Nanogen, and Gen-Probe. While serving as president of Osmetech, he successfully established the company as a fully integrated business, obtaining FDA clearance for four molecular diagnostic microarray products…

TuesdayNov 27, 2012 5:22 pm

EntreMed, Inc. (ENMD) Announces Publication of Results of Breast Cancer Preclinical Study

EntreMed, a clinical-stage pharmaceutical company developing targeted therapeutics for the treatment of cancer, announced the publication of favorable results of a preclinical study in breast cancer of its oral Aurora A/angiogenic kinase inhibitor, ENMD-2076. The article is titled “Predictive Biomarkers of Sensitivity to the Aurora and Angiogenic Kinase Inhibitor ENMD-2076 in Preclinical Breast Cancer Models.” The reports state findings that ENMD-2076 was able to provide anticancer activity against breast cancer cell lines lacking expression of the estrogen receptor (ER), progesterone receptor (PR) and without HER2‑amplification. Candidate predictive biomarkers were also identified which may be useful in selecting patients that are…

TuesdayNov 27, 2012 5:21 pm

Prana Biotechnology Ltd. (PRAN) Completes Patient Enrollment in Alzheimer Trial

Australia-based Prana Biotechnology is focused on commercializing research into age-related neurodegenerative disorders such as Alzheimer’s, Parkinson’s, and Huntington’s diseases. The company’s research centers on the interactions between certain metals in the human body and proteins. The company announced today that it has completed enrollment in the IMAGINE trial, a 12-month Phase II trial testing PBT2, the company’s drug in development for Alzheimer’s disease. This disease affects more than 26 million people around the globe. All currently available treatments only offer some degree of symptomatic relief, but none change the course of the disease. PBT2 has the potential to actually treat…

TuesdayNov 27, 2012 5:20 pm

Shoreline Energy Corp. (SEQ.TO) to Provide Investor Update via Conference Call Tomorrow

Shoreline Energy Corp. is planning to hold a conference call tomorrow, November 28, 2012, to discuss its recent business developments, including the impact and outlook relating to its acquisition of the Wattenberg Colorado Project located in the Denver-Julesberg Basin. The Wattenberg Colorado Project represents Shoreline’s initial entry into the United States. This project is currently an area of a large scale, low risk horizontal development well program, using multi-stage frac technology. Acquisition of the project is expected to generate $4.6m of cash flows the first year, providing an initial rate of return of more than 30%. The CEO of Shoreline…

Site Search

Company Search